Search

Your search keyword '"Wang, Yun F. (Wayne)"' showing total 23 results
Start Over Author "Wang, Yun F. (Wayne)"
23 results on '"Wang, Yun F. (Wayne)"'

5. Covid‐19 will not “magically disappear”: Why access to widespread testing is paramount

Author

George, Paul E., primary, Stokes, Claire L., additional, Bassit, Leda C., additional, Chahroudi, Ann, additional, Figueroa, Janet, additional, Griffiths, Mark A., additional, Heilman, Stacy, additional, Ku, David N., additional, Nehl, Eric J., additional, Leong, Traci, additional, Levy, Joshua M., additional, Kempker, Russell R., additional, Mannino, Robert G., additional, Mavigner, Maud, additional, Park, Sunita I., additional, Rao, Anuradha, additional, Rebolledo, Paulina A., additional, Roback, John D., additional, Rogers, Beverly B., additional, Schinazi, Raymond F., additional, Suessmith, Allie B., additional, Sullivan, Julie, additional, Tyburski, Erika A., additional, Vos, Miriam B., additional, Waggoner, Jesse J., additional, Wang, Yun F. (Wayne), additional, Madsen, Jen, additional, Wechsler, Daniel S., additional, Joiner, Clinton H., additional, Martin, Greg S., additional, and Lam, Wilbur A., additional

Published
2020
Full Text
View/download PDF

7. Loss of Smell and Taste Among Healthcare Personnel Screened for Coronavirus 2019.

Author

Kempker, Russell R, Kempker, Jordan A, Peters, Marcia, Rebolledo, Paulina A, Carroll, Kelley, Toomer, Linda, Wang, Yun F (Wayne), Ray, Susan M, and Hunter, Mary

Subjects
COVID-19, AGEUSIA, SICK people, MEDICAL personnel, MEDICAL screening, SMELL disorders, SYMPTOMS, DESCRIPTIVE statistics
Abstract

Among 283 symptomatic healthcare personnel (HCP) tested for SARS-CoV-2, 51 (18%) were positive. Among those 51 HCP, self reported loss of smell and taste were present in 51% and 52.9%, respectively, with either present in 60.8%. These symptoms had high specificity (93% each, 96% for either) for a positive SARS-CoV-2 test. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

8. The need for new test verification and regulatory support for innovative diagnostics

Author

Roback, John D., Tyburski, Erika A., Alter, David, Asakrah, Saja, Chahroudi, Ann, Esper, Annette, Farmer, Sarah, Figueroa, Janet, K. Frediani, Jennifer, D. Gonzalez, Mark, S. Gottfried, David, Guarner, Jeannette, A. Gupta, Nitika, S. Heilman, Stacy, E. Hill, Charles, Jerris, Robert, R. Kempker, Russell, Ingersoll, Jessica, Levy, Joshua M., Mavigner, Maud, S. Moreno, Carlos, R. Morris, Claudia, J. Nehl, Eric, S. Neish, Andrew, Peker, Deniz, Saakadze, Natia, Rebolledo, Paulina A., A. Rostad, Christina, Schoof, Nils, Suessmith, Allie, Sullivan, Julie, Wang, Yun F. (Wayne), Wood, Anna, Vos, Miriam B., Brand, Oliver, Martin, Greg S., and Lam, Wilbur A.

Published
2021
Full Text
View/download PDF

14. Multilaboratory Evaluation of Real-Time PCR Tests for Hepatitis B Virus DNA Quantification

Author

Caliendo, Angela M., primary, Valsamakis, Alexander, additional, Bremer, James W., additional, Ferreira-Gonzalez, Andrea, additional, Granger, Suzanne, additional, Sabatini, Linda, additional, Tsongalis, Gregory J., additional, Wang, Yun F. (Wayne), additional, Yen-Lieberman, Belinda, additional, Young, Steve, additional, and Lurain, Nell S., additional

Published
2011
Full Text
View/download PDF

17. Signal Amplification Techniques: bDNA, Hybrid Capture.

Author

Yi-Wei Tang, Stratton, Charles W., and Wang, Yun F. (Wayne)

Abstract

Signal amplification technology has unique features and even some advantages over target amplification systems for direct detection or quantification of target nucleic acid sequences. Reliable detection is achieved without the need for dedicated or isolated lab space or concern regarding inhibition and contamination that could be found in target amplification assays. The bDNA and hybrid capture technologies provide uncomplicated assay procedures, high throughput, and reliable signal amplification tests for diagnosis of viral or bacterial infection in routine clinical laboratories. [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

18. Advanced Antibody Detection.

Author

Yi-Wei Tang, Stratton, Charles W., and Wang, Yun F. (Wayne)

Abstract

Over the past 20 years, immunodiagnostic technologies have been developed to identify infectious agents with better sensitivity and specificity to ensure that every true-positive case is diagnosed. Antibody-based methods used to be the tool for the detection and epidemiological analysis of slow-growing, difficult-to-culture, uncultivatable, or emerging infectious agents. Conventional ELISA has been the predominant technology used for such assays, with CLIA, ECL, and TRF detection formats becoming more promising technologies for automated antibody detection. Handheld assay and multiplexed flow cytometry methods are also emerging as the next generation of rapid laboratory-based technologies. [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

19. Probability of Negative Mycobacterium tuberculosisComplex Cultures Based on Time to Detection of Positive Cultures: a Multicenter Evaluation of Commercial-Broth-Based Culture Systems

Author

Tyrrell, Frances C., Budnick, Gary E., Elliott, Thor, Gillim-Ross, Laura, Hildred, Mary V., Mahlmeister, Peggy, Parrish, Nicole, Pentella, Michael, Vanneste, Jolene, Wang, Yun F. (Wayne), and Starks, Angela M.

Abstract

ABSTRACTWe conducted a multicenter study to determine whether Mycobacterium tuberculosiscomplex (MTBC) cultures in automated broth-based systems could reliably be considered negative sooner than 6 weeks. Laboratory sites used Bactec MGIT or BacT/Alert and tracked results of time to detection of all mycobacteria (TTD-all, n= 1547) and of MTBC (TTD-MTBC, n= 466) over 6-month periods from primarily (93%) respiratory specimens. Cumulative percentages by day detected and median TTD of initial and follow-up specimens were analyzed. The median TTD-MTBC for MGIT (n= 6 sites) was 14 days. For laboratories using standard processing procedures, 100% of MTBC were detected from initial and follow-up specimens in 28 and 35 days, respectively, and no yield of MTBC on solid or MGIT liquid media was observed after 5 weeks. The median TTD-MTBC for BacT/Alert (n= 3 sites) was 18 days, with 95% and 100% detected within 37 and 42 days, respectively. Analysis of TTD of positive MTBC cultures in broth can predict the probability of culture negativity at defined time points. Receipt of interim negative reports earlier than 6 weeks could assist clinicians in considering alternative diagnoses and could alter the timing and prioritization of public health interventions. Laboratories should analyze their own TTD data to inform protocol decisions. Laboratories using MGIT could issue reports of no growth of MTBC on initial specimens as early as 4 weeks and for patients undergoing treatment as early as 5 weeks postinoculation.

Published
2012
Full Text
View/download PDF

20. Recurrent Staphylococcus lugdunensisInfective Endocarditis and Review of the Literature

Author

Jung, Jesse J., Yoo, Dale, Law, Karen, Wang, Yun F. (Wayne), and Higgins, Stacy

Abstract

Coagulase-negative staphylococcal species are generally considered commensal inhabitants of the skin. Often regarded as avirulent organisms, certain species such as Staphylococcus lugdunensishave been identified as the cause of severe human infections including infective endocarditis. We report on a case of a native valve, S. lugdunensisinfective endocarditis relapse after initial conservative medical therapy. A literature review of the outcomes of treatment was also performed. Analyzing definitive medical versus medical-surgical treatment of native valve infective endocarditis, an odds ratio of mortality of 3.1875 (95% confidence interval CI, 1.1855-8.5705; P< 0.03) was obtained and was significant based on 2-tailed Fisher exact probability test. This analysis reveals an increase risk of mortality with medical therapy alone versus medical-surgical therapy for native valve infective endocarditis. Our case and review of the literature emphasize the growing evidence that early medical treatment and surgical evaluation and removal of infected foreign hardware is required to prevent significant morbidity and mortality.

Published
2010
Full Text
View/download PDF

21. The lab's increasing arsenal of tools to battle antibiotic resistance.

Author

Wang, Yun F (Wayne)

Subjects
*ANTIBIOTICS, *MASS spectrometry methodology, *DRUG resistance in microorganisms, *PATHOLOGICAL laboratories, *SOCIAL role, *DECISION making in clinical medicine, *TURNAROUND time
Abstract

The article offers information on the tools and technology being used in clinical microbiology laboratory to fight multidrug-resistant organisms (MDROs). It says that Grady Health System in Atlanta, Georgia acquired a so-called cutting-edge tool that can give data on pathogen identification and antimicrobial susceptibility (AMS). It says that the Matrix Assisted Laser Desorption Ionization Time of Flight Mass Spectometry (MALDI-TOF MS) helps bypass time-consuming tasks in culturing pathogen.

Published
2011

22. Rapid laboratory diagnosis for respiratory infectious diseases by using MALDI-TOF mass spectrometry.

Author

Wang YF and Fu J

Abstract

It is still challenging to prevent and treat respiratory infectious diseases. One critical step in the successful treatment of respiratory infections is rapid diagnosis by identifying the causative microorganisms in a timely fashion. However, traditional methods for identification of causative agents could not satisfy the need for rapid and accurate testing due to the limitations of technology-used. In recent years, matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS) has been validated and used for rapid identification of microorganism and for potential discovery of diseases associated biomarkers. We reviewed recent advances of MALDI-TOF-MS as the laboratory diagnostic tool for the rapid laboratory diagnosis of microorganisms associated with respiratory infectious diseases, with the focus on rapid identification of pathogenic bacteria and molecular markers discovery using MALDI-TOF-MS. With the advanced technologies such as MALDI-TOF, early and targeted therapies based on rapid identification of pathogens and could lead to quick and effective treatment of respiratory infections and better patient management.

Published
2014
Full Text
View/download PDF

23. Probability of negative mycobacterium tuberculosis complex cultures based on time to detection of positive cultures: a multicenter evaluation of commercial-broth-based culture systems.

Author

Tyrrell FC, Budnick GE, Elliott T, Gillim-Ross L, Hildred MV, Mahlmeister P, Parrish N, Pentella M, Vanneste J, Wang YF, and Starks AM

Subjects
Automation methods, Humans, Time Factors, Bacteriological Techniques methods, Mycobacterium tuberculosis isolation & purification, Tuberculosis diagnosis, Tuberculosis microbiology
Abstract

We conducted a multicenter study to determine whether Mycobacterium tuberculosis complex (MTBC) cultures in automated broth-based systems could reliably be considered negative sooner than 6 weeks. Laboratory sites used Bactec MGIT or BacT/Alert and tracked results of time to detection of all mycobacteria (TTD-all, n = 1547) and of MTBC (TTD-MTBC, n = 466) over 6-month periods from primarily (93%) respiratory specimens. Cumulative percentages by day detected and median TTD of initial and follow-up specimens were analyzed. The median TTD-MTBC for MGIT (n = 6 sites) was 14 days. For laboratories using standard processing procedures, 100% of MTBC were detected from initial and follow-up specimens in 28 and 35 days, respectively, and no yield of MTBC on solid or MGIT liquid media was observed after 5 weeks. The median TTD-MTBC for BacT/Alert (n = 3 sites) was 18 days, with 95% and 100% detected within 37 and 42 days, respectively. Analysis of TTD of positive MTBC cultures in broth can predict the probability of culture negativity at defined time points. Receipt of interim negative reports earlier than 6 weeks could assist clinicians in considering alternative diagnoses and could alter the timing and prioritization of public health interventions. Laboratories should analyze their own TTD data to inform protocol decisions. Laboratories using MGIT could issue reports of no growth of MTBC on initial specimens as early as 4 weeks and for patients undergoing treatment as early as 5 weeks postinoculation.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results